Additionally, Phase I clinical trials have demonstrated that PMX53, a cyclic peptide acting as a C5aR1 antagonist, is safe for oral administration in the treatment of rheumatoid arthritis (76, 77). This evidence concerns the gene C5AR1 and rheumatoid arthritis.